BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 18538481)

  • 21. Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer.
    Gupta P; Jani KA; Yang DH; Sadoqi M; Squillante E; Chen ZS
    Expert Opin Drug Metab Toxicol; 2016; 12(3):281-9. PubMed ID: 26799671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
    Talekar M; Kendall J; Denny W; Garg S
    Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
    Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
    Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer chemotherapy with lipid-based nanocarriers.
    Liu D; Zhang N
    Crit Rev Ther Drug Carrier Syst; 2010; 27(5):371-417. PubMed ID: 21083528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer.
    Lee WH; Loo CY; Leong CR; Young PM; Traini D; Rohanizadeh R
    Expert Opin Drug Deliv; 2017 Aug; 14(8):937-957. PubMed ID: 27759437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(22):3301-3308. PubMed ID: 28403792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent progress in nanomedicine for enhanced cancer chemotherapy.
    Wei G; Wang Y; Yang G; Wang Y; Ju R
    Theranostics; 2021; 11(13):6370-6392. PubMed ID: 33995663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrasound-mediated nano drug delivery for treating cancer: Fundamental physics to future directions.
    Moradi Kashkooli F; Jakhmola A; Hornsby TK; Tavakkoli JJ; Kolios MC
    J Control Release; 2023 Mar; 355():552-578. PubMed ID: 36773959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The new era of pancreatic cancer treatment: Application of nanotechnology breaking through bottlenecks.
    Luo W; Zhang T
    Cancer Lett; 2024 Jul; 594():216979. PubMed ID: 38795762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic and diagnostic applications of nanoparticles.
    Youns M; Hoheisel JD; Efferth T
    Curr Drug Targets; 2011 Mar; 12(3):357-65. PubMed ID: 20955146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
    Gote V; Nookala AR; Bolla PK; Pal D
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-based drug delivery systems for cancer treatment.
    Arias JL; Clares B; Morales ME; Gallardo V; Ruiz MA
    Curr Drug Targets; 2011 Jul; 12(8):1151-65. PubMed ID: 21443475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
    Zhang Q; Li F
    Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered multifunctional nanocarriers for cancer diagnosis and therapeutics.
    Shi D; Bedford NM; Cho HS
    Small; 2011 Sep; 7(18):2549-67. PubMed ID: 21648074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.
    Niazi M; Zakeri-Milani P; Najafi Hajivar S; Soleymani Goloujeh M; Ghobakhlou N; Shahbazi Mojarrad J; Valizadeh H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1021-33. PubMed ID: 27267126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced anticancer activity and circumvention of resistance mechanisms by novel polymeric/ phospholipidic nanocarriers of doxorubicin.
    Senkiv Y; Riabtseva A; Heffeter P; Boiko N; Kowol CR; Jungwith U; Shlyakhtina Y; Garasevych SG; Mitina N; Berger W; Zaichenko A; Stoika R
    J Biomed Nanotechnol; 2014 Jul; 10(7):1369-81. PubMed ID: 24804557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress in nanotechnology for cancer therapy.
    Tang MF; Lei L; Guo SR; Huang WL
    Chin J Cancer; 2010 Sep; 29(9):775-80. PubMed ID: 20800018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological strategies for overcoming multidrug resistance.
    Nobili S; Landini I; Giglioni B; Mini E
    Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug targeting strategies in cancer treatment: an overview.
    Arias JL
    Mini Rev Med Chem; 2011 Jan; 11(1):1-17. PubMed ID: 21235512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.